Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma
- PMID: 34095952
- DOI: 10.1093/bjs/znab162
Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma
Abstract
Background: Long-term survival outcomes of trimodal therapy (TMT; chemoradiation plus surgery) and bimodal therapy (BMT; chemoradiation) have seldom been analysed. In a selective-surgery paradigm, the benefit of TMT in patients with a complete clinical response is controversial. Factors associated with survival in patients with a clinical complete response to chemoradiation were evaluated.
Methods: Patients with stage II-III oesophageal squamous cell carcinoma treated with TMT or BMT from 2002 to 2017 were evaluated. The BMT group consisted of patients who were otherwise eligible for surgery but underwent chemoradiation alone followed by observation. This group included patients who later had salvage oesophagectomy. Survival was evaluated and compared between TMT and BMT groups. Elastic net regularization was performed to select co-variables for Cox multivariable survival analysis in patients with a clinical complete response.
Results: Of 143 patients, 60 (41.9 per cent) underwent TMT and 83 (58.0 per cent) BMT. Patients who underwent TMT had longer median overall survival than those who had BMT (77 versus 33 months; P = 0.019). For patients with a clinical complete response, TMT achieved longer median overall survival than BMT (123 versus 55 months; P = 0.04). BMT had a high locoregional recurrence rate (48 versus 6 per cent; P < 0.001); 26 of 29 patients with locoregional recurrence in the BMT groupunderwent salvage resection. Cox multivariable analysis demonstrated that upper-mid oesophageal tumour location (hazard ratio (HR) 2.04; P = 0.024) and tumour length (HR 1.18; P = 0.046) were associated with worse survival. Although TMT was not associated with survival, it was a predictor of reduced recurrence (HR 0.28; P = 0.028). The maximum standardized uptake value after chemoradiation also predicted recurrence (HR 1.33; P < 0.001).
Conclusion: In patients who achieve a clinical complete response, TMT reduces locoregional recurrence but may not prolong survival. The differences in survival outcomes may be due to patient selection; therefore, a selective-surgery strategy in oesophageal squamous cell carcinoma is a reasonable approach.
© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all?Interact Cardiovasc Thorac Surg. 2013 Sep;17(3):460-6. doi: 10.1093/icvts/ivt216. Epub 2013 May 31. Interact Cardiovasc Thorac Surg. 2013. PMID: 23728085 Free PMC article.
-
The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa-IVa lower thoracic oesophageal squamous cell carcinoma.World J Surg Oncol. 2018 Nov 7;16(1):216. doi: 10.1186/s12957-018-1516-1. World J Surg Oncol. 2018. PMID: 30404621 Free PMC article.
-
The Impact of Pretreatment PET/CT Nodal Status on Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiation.World J Surg. 2020 Jul;44(7):2323-2331. doi: 10.1007/s00268-020-05481-7. World J Surg. 2020. PMID: 32296872
-
The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.Int J Surg. 2018 Dec;60:88-100. doi: 10.1016/j.ijsu.2018.10.037. Epub 2018 Oct 31. Int J Surg. 2018. PMID: 30389537
-
Endoscopic resection for residual oesophageal neoplasia after definitive chemoradiotherapy.Best Pract Res Clin Gastroenterol. 2024 Feb;68:101885. doi: 10.1016/j.bpg.2024.101885. Epub 2024 Jan 31. Best Pract Res Clin Gastroenterol. 2024. PMID: 38522883 Review.
Cited by
-
Association of interleukin-10 rs1800896, rs1800872, and interleukin-6 rs1800795 polymorphisms with squamous cell carcinoma risk: A meta-analysis.Open Life Sci. 2023 Apr 15;18(1):20220580. doi: 10.1515/biol-2022-0580. eCollection 2023. Open Life Sci. 2023. PMID: 37077342 Free PMC article.
-
Collaborative multidisciplinary management and expertise of cT2-3 locally advanced operable esophageal squamous cell carcinoma: a report of two cases.J Thorac Dis. 2023 Nov 30;15(11):6362-6372. doi: 10.21037/jtd-23-1277. Epub 2023 Nov 21. J Thorac Dis. 2023. PMID: 38090303 Free PMC article.
-
Long-term survival outcomes of esophageal squamous cell carcinoma with intraoperative thoracic duct ligation: a large-scale propensity score matching analysis.Front Oncol. 2025 Mar 5;15:1533378. doi: 10.3389/fonc.2025.1533378. eCollection 2025. Front Oncol. 2025. PMID: 40110202 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical